Hilliard Marisa E, Eakin Michelle N, Borrelli Belinda, Green Angela, Riekert Kristin A
Johns Hopkins University School of Medicine, Johns Hopkins Adherence Research Center, Division of Pulmonary and Critical Care Medicine.
Warren Alpert School of Medicine at Brown University.
Health Psychol. 2015 May;34(5):496-504. doi: 10.1037/hea0000136. Epub 2014 Aug 11.
Depression is a known barrier to regimen adherence for chronic conditions. Despite elevated depression rates and complex regimens for people with cystic fibrosis (CF), little is known about associations between depressive symptoms and CF adherence. One possibility is that depressive symptoms distort beliefs about medications, which may influence adherence.
Adolescents and adults (N = 128; mean age = 29 ± 11 years, range = 16-63, 93% Caucasian) with CF reported on depressive symptoms and medication beliefs (self-efficacy, motivation, perceived importance, and outcome expectancies related to taking medications). Medication adherence was assessed objectively through pharmacy refill data. Cross-sectional structural equation models evaluated medication beliefs as a mediator between depressive symptoms and medication adherence.
Twenty-three percent of participants exceeded clinical cutoffs for depressive symptoms. Participants took less than half of prescribed pulmonary medications (mean adherence rate = 44.4 ± 26.7%). Depressive symptoms were correlated with adherence (r = -.22, p < .05), and medication beliefs (b = -0.13, 95% CI [-0.24, -0.03]) significantly mediated this relation. Higher depressive symptoms were associated with less positive medication beliefs (b = -0.27, p < .01), which were associated with lower medication adherence (b = 0.49, p < .01).
Depressive symptoms are related to beliefs about and adherence to CF medications. Monitoring depressive symptoms and medication beliefs in routine CF care may help identify risks for nonadherence and facilitate interventions to reduce depression, adaptive medication beliefs, and ultimately improve adherence and CF management. (PsycINFO Database Record
抑郁症是慢性病患者坚持治疗方案的已知障碍。尽管囊性纤维化(CF)患者的抑郁症发病率较高且治疗方案复杂,但对于抑郁症状与CF治疗依从性之间的关联却知之甚少。一种可能性是,抑郁症状会扭曲对药物的信念,这可能会影响治疗依从性。
患有CF的青少年和成年人(N = 128;平均年龄 = 29 ± 11岁,范围 = 16 - 63岁,93%为白种人)报告了抑郁症状和药物信念(自我效能感、动机、感知重要性以及与服药相关的结果预期)。通过药房配药数据客观评估药物治疗依从性。横断面结构方程模型评估药物信念作为抑郁症状与药物治疗依从性之间的中介。
23%的参与者抑郁症状超过临床临界值。参与者服用的肺部处方药不到一半(平均依从率 = 44.4 ± 26.7%)。抑郁症状与依从性相关(r = -0.22,p < 0.05),药物信念(b = -0.13,95%可信区间[-0.24,-0.03])显著介导了这种关系。较高的抑郁症状与较消极的药物信念相关(b = -0.27,p < 0.01),而消极的药物信念又与较低的药物治疗依从性相关(b = 0.49,p < 0.01)。
抑郁症状与对CF药物的信念及依从性有关。在常规CF护理中监测抑郁症状和药物信念可能有助于识别不依从的风险,并促进采取干预措施来减轻抑郁、形成适应性药物信念,最终提高依从性和CF管理水平。(《心理学文摘数据库记录》